Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000262119 is annotated in the human genome as a novel transcript located entirely within an intron of the NOVA1 gene, transcribed in the same direction as NOVA1. There is currently no evidence that it codes for a protein, nor that it acts as a validated regulatory RNA or functional target. Unlike NOVA1, which encodes a well-known neuron-specific RNA-binding protein with critical roles in alternative splicing[1][3], this particular transcript has neither demonstrated biological activity nor established links to therapeutic targeting, disease association, or pharmacological modulation. Major genomics databases recognize its sequence but do not class it as a gene encoding a receptor, enzyme, transporter, or other canonical therapeutic target class. Therefore, it should not be considered a molecular therapeutic target under current guidelines. Key notes: - The description of this entry as a "novel transcript, sense intronic to NOVA1" indicates an uncharacterized or predicted genomic feature, not an established gene or druggable target[1][3]. - Naming conventions and genomic annotations frequently include such predicted transcripts; however, without supporting functional or experimental data, these do not fulfill established target criteria[5]. - No aliases, molecular classifications, or pharmacological roles have been identified. - ENSG00000262119 is not equivalent to NOVA1 and should not be conflated with it—the latter is a functionally characterized splicing regulator involved in neuronal biology[1][3]. - If "therapeutic target" means a molecule that can presently be modulated by drugs/therapies and is relevant to disease, this entry should not be classified as such. If you intend to refer to the well-established NOVA1 protein (Neuro-oncological ventral antigen 1), refer instead to "NOVA1" (canonical gene ENSG00000139910), an RNA-binding splicing factor with a neurological regulatory role[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, sense intronic to NOVA1 (ENSG00000262119).